News | December 22, 2008

First Time NanoKnife Treats Lung Lesion, Lymph Node Metastasis

December 23, 2008 — The Alfred in Melbourne, Australia, used AngioDynamics’s NanoKnife system, which leverages irreversible electroporation (IRE) technology, on a lymph node metastasis and the first lung lesion case.

Ken Thomson, M.D., professor and director of the Department of Radiology at The Alfred, Monash University, performed the procedures, which the institution deemed successful from a safety perspective. The hospital will conduct further patient follow-up before determining final outcomes in terms of tumor response.

NanoKnife causes cell death by impacting the cell membranes of targeted tissue with pulses of electricity, effectively sparing nearby nerves, blood vessels, lymphatic system and other delicate structures. Targeted cells are removed from the body through blood vessels and lymphatic systems. This is different from thermal ablation modalities like cryoablation, microwave and radiofrequency ablation. These other modalities destroy all cells including critical structures in targeted tissue, leaving destroyed material in place for years. The body can only remove it slowly by attacking from the outside, as all normal pathways to remove damaged tissue have been destroyed.

“For the patient, the absence of post-operative pain is unique and remarkable,” said Dr. Thomson. “We have also treated tumors in the liver and kidney with NanoKnife, with similar experiences – no postoperative pain at all – and the procedures have raised no safety concerns. This is probably due to the fact that the supporting structure of the tissue treated is not destroyed and vascular and nerve function is unaffected.”

Regarding a previously announced liver case from The Alfred, sequential triple phase liver CT scans and ultrasound at two weeks and four weeks post-procedure have shown that a 2-cm tumor has disappeared on imaging. At the site of a 3.5-cm tumor near the diaphragm in the same patient there is only a minor nonenhancing scar. Dr Thomson noted these outcomes contrast very favorably with the cavities left following thermal ablation procedures.

AngioDynamics intends to file investigational device exemptions (IDE) with the FDA to pursue additional and more specific tissue indications. The device has been cleared for a general soft tissue ablation indication by the Food and Drug Administration.

For more information: www.angiodynamics.com

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init